Xcovery Holdings
Privately held: no public share price
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Ensartinib(Ensacove) | Approved | ALKSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
February 2029 (1)
Est. primary completion 2029-02-01 · NCT07448116 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
9 July 2026Filing acceptedEnsartinibChina accepts the marketing application for adjuvant ensartinib in resected ALK-positive NSCLC
China, NMPA · Betta Pharmaceuticals Co. · Source ↗
Financial reports
No financial reports recorded.